Central sleep apnea in conditions classified elsewhere
Methodology & AI Transparency ⓘ
Central sleep apnea in conditions classified elsewhere Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Central sleep apnea in conditions classified elsewhere—coded clinically as G47.37 across Sleep Disorders guidelines—combines iron/thyroid screening [Central sleep apnea in conditions classified elsewhere G47.37] with structured follow-up of Apnea-Hypopnea Index (AHI) [Central sleep apnea in conditions classified elsewhere G47.37] (< 5 events/hour (G47.37)).
- 2 Real-world patient consensus: Clinical coding for Central sleep apnea in conditions classified elsewhere uses ICD-10 G47.37 across Sleep Disorders specialty care.
- 3 Typical cash cost range: Primary evaluation for Central sleep apnea in conditions classified elsewhere incorporates iron/thyroid screening [Central sleep apnea in conditions classified elsewhere G47.37] and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Central sleep apnea in conditions classified elsewhere: maintaining Serum Ferritin (Restless in Central sleep apnea in conditions classified elsewhere (G47.37: Legs)) within > 75 ng/mL (G47.37).
Ask our AI Specialists anything about Central sleep apnea in conditions classified elsewhere
What Is Central sleep apnea in conditions classified elsewhere?
Central sleep apnea in conditions classified elsewhere—coded clinically as G47.37 across Sleep Disorders guidelines—combines iron/thyroid screening [Central sleep apnea in conditions classified elsewhere G47.37] with structured follow-up of Apnea-Hypopnea Index (AHI) [Central sleep apnea in conditions classified elsewhere G47.37] (< 5 events/hour (G47.37)).
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Central sleep apnea in conditions classified elsewhere (code G47.37) is fragmented slow-wave/REM sleep in Central sleep apnea in conditions classified elsewhere (G47.37: architecture), which Insomnia, Sleep Apnea & Sleep Health clinicians address while surveilling Serum Ferritin (Restless in Central sleep apnea in conditions classified elsewhere (G47.37: Legs)) (> 75 ng/mL (G47.37)).
Common Symptoms & Clinical Signs
- • Presentation of Central sleep apnea in conditions classified elsewhere (G47.37): daytime microsleeps, cognitive in Central sleep apnea in conditions classified elsewhere (G47.37: brain fog, or)
- • Secondary Central sleep apnea in conditions classified elsewhere clinical sign: prolonged sleep-onset latency [Central sleep apnea in conditions classified elsewhere G47.37]
- • Symptom flares in Central sleep apnea in conditions classified elsewhere correlating with Serum Ferritin (Restless in Central sleep apnea in conditions classified elsewhere (G47.37: Legs)) deviation outside > 75 ng/mL (G47.37)
- • Functional sleep disorders impact requiring iron/thyroid screening [Central sleep apnea in conditions classified elsewhere G47.37] evaluation (G47.37)
Central sleep apnea in conditions classified elsewhere Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G47.37 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Insomnia, Sleep Apnea & Sleep Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: Serum Ferritin (Restless in Central sleep apnea in conditions classified elsewhere (G47.37: Legs)) | > 75 ng/mL (G47.37) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Apnea-Hypopnea Index (AHI) [Central sleep apnea in conditions classified elsewhere G47.37] | < 5 events/hour (G47.37) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Insomnia Severity Index in Central sleep apnea in conditions classified elsewhere (G47.37: (ISI)) | < 7 (G47.37) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Central sleep apnea in conditions classified elsewhere
Treatment selection for Central sleep apnea in conditions classified elsewhere depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Central sleep apnea in conditions classified elsewhere)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Relationship between obstructive sleep apnea hypopnea syndrome and chronic acid: What a 2,699-Participant Study Found The meta-analysis showed that there was a significant correlation between obstructive sleep apnea hypopnea syndrome and chronic acid reflux. Sleep & breathing = Schlaf & Atmung • 2019-06-15 • Meta-Analysis | N = 2,699 | 94/100 | PMID 29987514 ↗ |
| New Insights on Is adenotonsillectomy effective in improving central apnea events in patients: What a 1,287-Participant Study Found Adenotonsillectomy improves central apnea events in patients with OSA but not in those with comorbidities. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery • 2023-12-15 • Meta-Analysis | N = 1,287 | 94/100 | PMID 37642712 ↗ |
| New Insights on Meaningful Within-Patient Change on the trouble sleeping Daytime Symptoms and: What a 930-Participant Study Found This analysis demonstrates the meaningful within-patient change for the IDSIQ total score and domain scores, that the instrument is sensitive to changes in the patient experience of trouble sleeping, and that it can be used in... Pharmaceutical medicine • 2023-07-15 • Phase III Randomized Trial | N = 930 | 93/100 | PMID 37286927 ↗ |
| New Insights on Participant, site personnel and sponsor perspectives on decentralized trial: What a 486-Participant Study Found RVs influenced the decision to pursue the trial in 13/31 participants. Amyotrophic lateral sclerosis & frontotemporal degeneration • 2025-11-15 • Phase III Randomized Trial | N = 486 | 93/100 | PMID 40576049 ↗ |
| New Insights on SGLT2 inhibitor or metformin as standard treatment in early-stage type 2: What a 2,072-Participant Study Found This decentralised RRCT in newly onset T2D demonstrates a highly feasible option for large-scale trials in the primary care setting, enabling representative participant recruitment. Diabetes, obesity & metabolism • 2026-02-15 • Randomized Controlled Trial | N = 2,072 | 90/100 | PMID 41311237 ↗ |
Central sleep apnea in conditions classified elsewhere Patient Community & “People Like Me” Threads
Filter Central sleep apnea in conditions classified elsewhere community threads and patient logs by age, biological sex, dosage, and treatment duration.